Answers are grounded in this paper and cite their sources.
Although most patients with low-grade renal cell carcinoma treated with partial nephrectomy experience favorable outcomes, a subset develops recurrence, which negatively affects overall survival. This underscores the importance of long-term surveillance. Current National Comprehensive Cancer Network (NCCN) and American Urological Association (AUA) guidelines recommend imaging follow-up for 5 years in patients with pT1 renal cell carcinoma after partial nephrectomy,1 but there is no consensus on surveillance beyond that period. Decisions regarding extended imaging are typically left to informed/shared decision-making between clinicians and patients. Sandoval et al2 propose a structured long-term surveillance protocol, recommending imaging every 2 to 3 years for up to 10 years postoperatively. In their retrospective study of 310 patients with complete data, 28 (9%) experienced recurrence at a mean of 45.6 months. Importantly, 25% of these recurrences occurred after 5 years, with a mean time to recurrence of 93.4 months (7.78 years). Although cancer-specific mortality was low at 2%, recurrence was significantly associated with death (Hazard Ratio 4.42, P < .05). This study highlights a potential gap in current guidelines and suggests that a low-frequency, extended surveillance strategy may help detect late recurrences and reduce cancer-specific mortality. However, it does not address critical factors that influence existing protocols, such as the cost of prolonged imaging, radiation exposure, and the importance of shared decision-making.3 Although prospective validation would be ideal, the low event rate and long latency make such trials financially and logistically challenging. Extending surveillance for all patients to detect a small percentage of late recurrences may not be sustainable, emphasizing the need for improved tumor genomics and biomarker-based risk stratification. These tools could help tailor follow-up protocols to those at highest risk, optimizing resource use while maintaining oncological vigilance.
No takes yet. Share an insight, caveat, or question.
Shaaban et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: